Global Blood Brain Barrier Technologies 2015-2030 - Novel CNS Drug Delivery Approaches
DUBLIN, May 15, 2015 /PRNewswire/ --Research and Markets
(http://www.researchandmarkets.com/research/jqp8cl/bbb_technologies) has announced the addition of the "BBB Technologies: Novel CNS Drug Delivery Approaches, 2015 - 2030" report to their offering.
The BBB Technologies: Novel CNS Drug Delivery Approaches, 2015 - 2030' report provides an extensive study of the emerging market of BBB technologies and associated drugs for neurologic diseases. The focus of this study is primarily on the technologies that are non-invasive in nature. There are other technologies which either disrupt the barrier or use an alternate route to bypass it. These technologies are, for the purpose of this report, considered competing in nature.
The report covers various aspects such as research pipeline, technological profiles, recent developments and sales forecast to assess new evolving opportunities. We have also provided a competitive market analysis to compare the potential that resides in the leading neurological indications, such as Parkinson's disease, Alzheimer's disease, multiple sclerosis and brain cancer, for which BBB permeable drugs are being developed.
In addition to the well-known technologies, we have also provided case studies on four other technologies; these are either in direct competition or have been previously worked upon. Our opinion and insights, presented in this study, were influenced by the discussions that we conducted with different technology providers in this industry.
One of the key objectives of this report is to understand the future state of the BBB technologies market.
This is done by analyzing the following:
- Pipeline candidates based on these technologies
- Size of target consumer segments
- Expected launch year and countries where these clinical stage candidates are likely to receive commercialization rights
- Likely price points
The base year for the report is 2014. The report provides market forecasts for the period 2019 - 2030. The figures mentioned in this report are in USD, unless otherwise specified.
Key Topics Covered:
1. Preface
2. Executive Summary
3. Blood Brain Barrier: An Introduction
4. Market Overview
5. Neurological Indications: Market Potential
6. BBB Technologies: Underlying Concepts
7. BBB Technology Profiles
8. Case Studies
9. BBB Technologies: Market Forecasting
10. Interview Transcripts
11. Conclusion
12. Appendix 1: Tabulated Data
13. Appendix 2: List Of Companies
Companies Mentioned
- Abbott
- AbbVie
- Accera
- Acelot
- Acorda
- Acyclone Life Sciences
- Advanced BioHealing
- Aescap Ventures
- Affectis Pharmaceuticals
- Agate Medical Investments
- ALS association
- Angiochem
- Antea
- Aphios
- ArmaGen
- ArQule
- Array BioPharma
- Arrowhead Research Corp
- Artenga
- ASCIL Biopharma
- Asebio
- Atlas Venture
- Aurin Biotech
- AZ Therapies
- Bach Pharma
- Bayer
- BBB Therapeutics
- BDC Venture Capital
- BGN Technologies
- Bind Therapeutics
- BioAdvance
- Bioasis
- Biocat
- Biocrea
- Biogen Idec
- Bioline Rx
- BioMarin
- Biovista
- BMS
- Boehringer Ingelheim
- Boehringer Ingelheim Venture Fund
- Boston Scientific
- BPI France
- BrainsGate
- CarThera
- CDTI
- CEA
- Cerecor
- Chronos Therapeutics
- Cib-Geigy
- Cipio Partners
- CNRS
- Cortice Biosciences
- Corvitex
- Crinetics
- Cyclenium
- Dainippon Sumitomo Pharma
- Debiopharm
- Deciphera
- DEKK-TEC
- Del Mar Pharma
- Drugs Ford
- EIP Pharma
- Eisai
- Elan Pharmaceuticals
- Elron Electronic Industries Ltd
- Ethris GmbH
- Evgen
- FerroKinBioSciences
- Flocel
- Fluorinov Pharma
- Fondazione Telethon
- Forest Laboratories
- Genervon Biopharmaceuticals
- Genzyme
- GlaxoSmithKline
- Global Investment
- Heptares
- ICB International
- Immune Pharmaceuticals
- Impax Labs
- Impel Neuro Pharma
- ImStar
- Infinity
- INSERM
- Iproteos
- IRB Barcelona
- Janssen
- JCR Pharma
- Johnson & Johnson
- Jonghoud International BV
- Kadmon Corporation
- KalGene
- Krisani Bio
- Lixte
- Lotus Tissue
- Lumena Pharmaceuticals
- Lundbeck Pharmaceuticals
- Medesis Pharma
- MedImmune
- Medtronic
- Merck
- Michael J. Fox Foundation
- Minoryx
- Mitsui & Co.
- MMV financial
- Morphotek
- Movetis
- Mylan
- Mystic Pharmaceuticals
- nanoLIMIT Therapeutics
- Nanomerics
- Nativis
- Nektar Therapeutics
- Neuraltus Pharma
- Neuren Pharmaceuticals
- NeuroAdjuvants
- Neuronix
- NeuroSolis
- NeuroTransit
- NeuroVive
- New River
- NewGen Therapeutics
- NexGenix
- Novartis
- Novogen
- NPS Pharma
- Nsgene
- OncoNanoBBB
- OptiNose
- Ortho-McNeil Pharmaceuticals
- Oryzon
- OSEO
- Ossianix
- Palobiofarma
- ParcCientific
- Parke-Davis
- Perfusion Technology
- Pervasis Therapeutics
- Pharmaphenix
- Pharmadex
- Pharmidex Pharmaceutical Services
- Pitango Venture Capital
- Plexxikon
- Premacure AB
- Prexton Therapeutics
- Protagenic
- ProteoTech
- Prothena
- Protheragen
- PTC Therapeutics
- Radius Pharma
- Raptor
- Repligen
- Roche
- Sagetis Biotech
- SangamoBioSciences
- Sanofi
- Santaris Pharma
- Schering-Plough
- Schwarz Pharma
- SciFlourLife Sciences
- Shire
- Siena Biotech
- Sihuan
- SimPore
- SmithKline Beecham
- Solvo Biotechnology
- Sovicell
- Synageva BioPharma Corp
- Synageva BioPharma Corp.
- Synapse technologies
- Tactical Therapeutics
- Takeda
- Teva
- Teva Pharmaceuticals
- Transition Therapeutics
- Transmolecular Inc.
- UCB
- UCB Pharma
- Vect-Horus
- ViroPharma
- VistaGen Therapeutics
- VoltMed
- Xenoport
- Zywie
For more information visit http://www.researchandmarkets.com/research/jqp8cl/bbb_technologies
Media Contact: Laura Wood , +353-1-481-1716, press@researchandmarkets.net
Share this article